Farrell Simon - 16 Feb 2023 Form 4 Insider Report for Trevi Therapeutics, Inc. (TRVI)

Role
Chief Commercial Officer
Signature
/s/ Christopher Galletta, attorney-in-fact
Issuer symbol
TRVI
Transactions as of
16 Feb 2023
Transactions value $
$0
Form type
4
Date filed
16 Feb 2023, 16:30
Next filing
08 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRVI Stock Option (right to buy) Award $0 +100K $0.00 100K 16 Feb 2023 Common Stock 100K $2.67 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was granted on February 16, 2023. The 100,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 16, 2024 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 16, 2027.